Extended Data Fig. 1: Expression of GPR110 is reduced in human MASH liver and transcriptionally repressed by rosiglitazone.
a, Hepatic expression of GPR110 in patients with MASH and control individuals by analyzing the following GEO datasets: GSE159676 and GSE66676 (n = 54). b, Schematic diagram showing the locations of four predicted PPARγ response elements (PPREs, sequence indicated in red) within the promoter region of mouse Gpr110 gene as identified by in silico analysis with JASPAR (2024) and PROMO. c, Luciferase reporter assay on Gpr110 promoter in response to rosiglitazone treatment by truncation analysis. Hepa1-6 cells were transfected with luciferase-expressing vector driven by the Gpr110 promoter with different lengths as indicated. The cells were treated with rosiglitazone (20 μM) or DMSO control 4 hours post-transfection for 24 hours. The firefly luciferase activity was measured and normalized to renilla luciferase activity (n = 4/group). Data are presented as mean ± SD; Statistical significance was calculated using two-tailed Welch’s t-test (a) or two-tailed Student’s t-test (c).
